Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development.
Prior to joining Plus Therapeutics as the Chief Development Officer, from October 2021 through April 2026, Dr. Daniels served as the chief development officer of Kiora Pharmaceuticals (NASDAQ:KPRX). In addition, from 2018 through 2021, Dr. Daniels served as the executive director and co-founder of Bayon Therapeutics until it was acquired by Kiora Pharmaceuticals in October 2021 and as chief executive officer of OccuRx Pty Ltd., a clinical stage biotechnology company targeting microvascular disease for ocular indications, from July 2020 through October 2021. Dr. Daniels is also a co-founder and director of Okogen, Inc., a specialty biotechnology development stage ophthalmic company focused on a novel therapeutic for the treatment of viral infections of the eye, since May 2016. Since January 2014, Dr. Daniels has served on the clinical advisory board of Bimini, LLC and was chief medical officer of Bimini from January 2014 to October 2021. From April 2012 to November 2016, Dr. Daniels served as vice president – marketing & sales for Tensys Medical, Inc. (an HBM portfolio company). Dr. Daniels received his B.S. from the University of California Berkeley, his M.D. from the University of California, Los Angeles School of Medicine, and his MBA from the University of California, Los Angeles Anderson School of Management.